Detection of occult disease in breast cancer using fluorodeoxylucose camera-based positron emission tomography

Clinical Breast Cancer

Volumn 2, Issue 3, 2001, Pages 229-234

  Pecking, Alain P ^a   Mechelany Corone, Carine ^a   Bertrand Kermorgant, Françoise ^a   Alberini, Jean Louis ^a   Floiras, Jean Louis ^a   Goupil, Alain ^a   Pichon, Marie France ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Breast cancer; CA 15.3 tumor markers; Camera based PET; Occult disease

Indexed keywords

CA 15-3 ANTIGEN; FLUORODEOXYGLUCOSE F 18; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CAMERA; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OCCULT CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0035177864     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2001.n.026     Document Type: Article

References (24)

1. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators
2. CA 15-3 in patients with locoregional and metastatic breast carcinoma
3. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients
4. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
5. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
6. The management of metastatic bone disease in the United Kingdom
7. PET in oncology: Will it replace the other modalities?
8. Breast imaging with fluorine-18-FDG PET: Quantitative image analysis
9. Oncologic diagnosis with 2-[fluorine-18] fluoro-2-deoxy-D-glucose imaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner
10. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies
11. Detection en coincidence sur gamma camera conventionelle: Principles et performances
12. FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders
13. Positron-emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2[18F]fluoro-D-glucose
14. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET
15. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
16. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations
17. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience
18. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
19. Monoclonal antibodies in cancer detection and therapy
20. Increasing serum tumor markers as decision criteria for hormone therapy of metastatic breast cancer
21. Prolonged survival by 'early' salvage treatment of breast cancer patients: A retrospective 6-year study
22. Consensus statement: Guidelines for PSA following radiation therapy
23. Biochemical disease-free survival following 125I prostate implantation
24. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2